Commentary by Dr. Emile Daoud
Commentary by Dr. Emile Daoud
Commentary by Dr. Sadeer Al-Kindi and Dr. Mohamad Alkhouli
Commentary by Dr. Douglas Mann and Dr. Elena Amin and Mr. Seth Wagner
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Commentary by Dr. Candice Silversides
Sumanta Pal, MD, discusses the treatment of patients with metastatic renal cell carcinoma (mRCC), management of cardiovascular toxicities associated with therapies for mRCC, and the future treatment landscape of mRCC. Moderated by Sarah Waliany, MD, MS.
James Januzzi, MD, and Bonnie Ky, MD, MSCE discuss the discovery of novel biomarkers of cancer therapy-related cardiotoxicity. Moderated by Nicholas Wilcox, MD, MHS.
Dimitrios Farmakis, MD, PhD, and Bonnie Ky, MD, MSCE, discuss SGLT-2 inhibitors and genetics, and applications for cardio-oncology practice.
Commentary by Drs. Pratik Doshi and Martha Gulati discussing how we can improve diversity, equity, and inclusion efforts across cardiology.
Commentary by Dr. Emile Daoud
Commentary by Social Media Editor Anju Bhardwaj
Commentary by Dr. Emile Daoud
Commentary by Dr. Mary Norine Walsh